BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer
BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer
复制标题
DOI：
10.1593/neo.05406
复制
发表时间：
2005-12-01
期刊：
影响因子：
4.8
通讯作者：
Chen, WF
中科院分区：
文献类型：
--
作者：
Li, YY;Dong, XY;Chen, WF
利用生物信息学方法，我们克隆了一个新的肿瘤特异性基因BJ-TSA-9，并通过北方印迹分析和逆转录-聚合酶链反应（RT-PCR）进行了验证。BJ-TSA-9 mRNA在肺癌组织中的表达率为52.5%（21/40），在肺腺癌组织中表达率最高（68.8%）。为探讨BJ-TSA-9在肺癌患者循环癌细胞检测中的应用价值，采用巢式RT-PCR方法检测肺癌患者循环癌细胞。肺癌患者外周血单个核细胞（PBMCs）的总阳性检出率为34.3%（24/70），肺腺癌患者PBMCs的总阳性检出率为53.6%（15/28）。结合两个已知的标志基因SCC和LUNX的检测，检出率提高到81.4%。对37例手术切除肿瘤的患者进行了随访研究。在9名患者中，持续检测到2至3个肿瘤标志物转录在PBMC中，6名患者复发/转移。与此相反，28例短暂检测到一种肿瘤标志物或未检测到任何肿瘤标志物的患者均处于缓解状态。因此，BJ-TSA-9可作为肺癌诊断的标志物，并与其他两种肿瘤标志物组合作为预测肺癌患者复发和预后的标志物。
Using bioinformatics, we have identified a novel tumor-specific gene BJ-TSA-9, which has been validated by Northern blot analysis and reverse transcription-polymerase chain reaction (RT-PCR). BJ-TSA-9 mRNA was expressed in 52.5% (21 of 40) of human lung cancer tissues and was especially higher in lung adenocarcinoma (68.8%). To explore the potential application of BJ-TSA-9 for the detection of circulating cancer cells in lung cancer patients, nested RT-PCR was performed. The overall positive detection rate was 34.3% (24 of 70) in peripheral blood mononuclear cells (PBMCs) of patients with various types of lung cancers and was 53.6% (15 of 28) in PBMCs of lung adenocarcinoma patients. In combination with the detection of two known marker genes SCC and LUNX, the detection rate was increased to 81.4%. A follow-up study was performed in 37 patients after surgical removal of tumor mass. Among nine patients with persistent detection of two to three tumor marker transcripts in PBMCs, six patients had recurrence/metastasis. In contrast, 28 patients with transient detection of one tumor marker or without detection of any tumor marker were all in remission. Thus, BJ-TSA-9 may serve as a marker for lung cancer diagnosis and as a marker, in combination with two other tumor markers, for the prediction of the recurrence and prognosis of lung cancer patients.